Published in Transl Stroke Res on September 01, 2011
Protein nitration impairs the myogenic tone of rat middle cerebral arteries in both ischemic and nonischemic hemispheres after ischemic stroke. Am J Physiol Heart Circ Physiol (2013) 1.74
Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab (2013) 1.41
Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol (2012) 1.14
Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol (2013) 1.07
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke (2013) 1.01
Mixed cerebrovascular disease and the future of stroke prevention. Transl Stroke Res (2012) 0.97
Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci (2012) 0.96
Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res (2014) 0.95
Hyperbaric oxygen preconditioning attenuates hyperglycemia-enhanced hemorrhagic transformation by inhibiting matrix metalloproteinases in focal cerebral ischemia in rats. Exp Neurol (2013) 0.91
Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats. Brain Res (2013) 0.91
Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res (2013) 0.82
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA. Transl Stroke Res (2015) 0.81
Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res (2013) 0.81
SOD1 overexpression prevents acute hyperglycemia-induced cerebral myogenic dysfunction: relevance to contralateral hemisphere and stroke outcomes. Am J Physiol Heart Circ Physiol (2014) 0.78
Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation (2017) 0.78
Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke (2016) 0.77
4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol) (CNB-001) Does Not Regulate Human Recombinant Protein-Tyrosine Phosphatase1B (PTP1B) Activity in vitro. J Neurol Neurophysiol (2014) 0.75
Nox4 contributes to the hypoxia-mediated regulation of actin cytoskeleton in cerebrovascular smooth muscle. Life Sci (2016) 0.75
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke. J Neurol Neurophysiol (2014) 0.75
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke (2001) 6.32
Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci (2001) 4.99
Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke (1998) 3.58
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab (2003) 3.14
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med (2003) 3.10
Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol (2007) 2.92
Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab (1999) 2.41
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. Stroke (2003) 2.20
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology (2002) 2.02
Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke (2008) 1.91
Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab (2006) 1.87
Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology (2002) 1.79
Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes (2005) 1.74
Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke (2001) 1.73
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke (1999) 1.71
Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke (2004) 1.70
Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke (2007) 1.70
Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke (2007) 1.64
Experimental stroke in the female diabetic, db/db, mouse. J Cereb Blood Flow Metab (2001) 1.55
Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol (2007) 1.41
Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes (2009) 1.40
Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26
Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke (2009) 1.24
Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. Bioessays (2009) 1.23
Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab (2007) 1.15
Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract (2005) 1.12
Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med (1992) 1.10
Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther (2008) 1.08
Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem (2008) 1.01
Single slice method for quantification of hemorrhagic transformation using direct ELISA. Neurol Res (2004) 1.00
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther (2009) 0.99
Management of hyperglycemia in acute stroke: how, when, and for whom? Stroke (2008) 0.94
T cell adhesion to endothelial cells and extracellular matrix is modulated upon transendothelial cell migration. Lab Invest (1997) 0.87
The state of science and research in clinical pharmacy. Pharmacotherapy (2006) 7.26
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol (2005) 2.88
Remote ischemic perconditioning is effective alone and in combination with intravenous tissue-type plasminogen activator in murine model of embolic stroke. Stroke (2012) 2.46
SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol (2004) 1.94
Targets for vascular protection after acute ischemic stroke. Stroke (2004) 1.88
Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke (2011) 1.80
Protein nitration impairs the myogenic tone of rat middle cerebral arteries in both ischemic and nonischemic hemispheres after ischemic stroke. Am J Physiol Heart Circ Physiol (2013) 1.74
Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes (2005) 1.74
Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens (2007) 1.71
Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke (2010) 1.69
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci (2006) 1.69
Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens (2015) 1.58
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Ten months of exercise improves general and visceral adiposity, bone, and fitness in black girls. Obesity (Silver Spring) (2007) 1.57
Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol (2004) 1.47
Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol (2007) 1.41
Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes (2009) 1.40
Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther (2009) 1.30
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke (2009) 1.30
Impact of transcendental meditation on ambulatory blood pressure in African-American adolescents. Am J Hypertens (2004) 1.25
Minocycline for short-term neuroprotection. Pharmacotherapy (2006) 1.23
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke (2009) 1.23
Angiogenesis: a harmonized target for recovery after stroke. Stroke (2012) 1.22
Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol (2002) 1.21
Expression, subcellular localization, and regulation of sigma receptor in retinal muller cells. Invest Ophthalmol Vis Sci (2006) 1.20
A telestroke network enhances recruitment into acute stroke clinical trials. Stroke (2010) 1.19
Cytochrome c oxidase subunit IV as a marker of protein kinase Cepsilon function in neonatal cardiac myocytes: implications for cytochrome c oxidase activity. Biochem J (2004) 1.18
Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens (2006) 1.17
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res (2011) 1.17
Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther (2012) 1.15
Quantitation and localization of blood-to-brain influx by magnetic resonance imaging and quantitative autoradiography in a model of transient focal ischemia. Magn Reson Med (2005) 1.15
Decreased circulating leptin level and its association with body and bone mass in girls with adolescent idiopathic scoliosis. Spine (Phila Pa 1976) (2007) 1.15
Relationship of visceral adiposity to cardiovascular disease risk factors in black and white teens. Obesity (Silver Spring) (2007) 1.15
Cost-effectiveness of a school-based obesity prevention program. J Sch Health (2008) 1.14
Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vascul Pharmacol (2009) 1.14
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol (2007) 1.14
An environmental approach to obesity prevention in children: Medical College of Georgia FitKid Project year 1 results. Obes Res (2005) 1.13
Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol (2004) 1.11
Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol (2008) 1.11
Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol (2009) 1.11
Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci (2005) 1.11
Factors influencing outcome and treatment effect in PROACT II. Stroke (2003) 1.10
Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab (2010) 1.10
Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS One (2011) 1.10
Treatment of large impacted proximal ureteral stones: randomized comparison of percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. J Endourol (2008) 1.09
Expression and function of glutamine transporters SN1 (SNAT3) and SN2 (SNAT5) in retinal Müller cells. Invest Ophthalmol Vis Sci (2005) 1.08
Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther (2008) 1.08
Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol (2013) 1.07
Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke. Exp Transl Stroke Med (2011) 1.07
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther (2012) 1.07
CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor. NMR Biomed (2014) 1.06
Heart rate variability in adolescents: relations to physical activity, fitness, and adiposity. Med Sci Sports Exerc (2005) 1.05
Vascularization pattern after ischemic stroke is different in control versus diabetic rats: relevance to stroke recovery. Stroke (2013) 1.05